Abstract
cis-N-(1-Benzyl-2-methylpyrrolidine-3-yl)-5-iodo-2-methoxy-4-(methylamino)benzamide (IYM), a YM-09151-2 analog iodinated at the 5-position of the benzoyl moiety, was synthesized and evaluated as a potential radiopharmaceutical for investigating brain dopamine D 2 receptors by single photon emission computer tomography (SPECT). [ 125I]IYM was synthesized by a halogen exchange reaction and purified by high-performance liquid chromatography (HPLC). An in vitro competitive binding study with [ 3H]spiperone using rat striatal synaptosomal membranes revealed that IYM had higher affinity for dopamine D 2 receptors than did YM-09151-2 or spiperone. In a saturation binding study using rat striatal synaptosomal membranes, IYM had a K d of 0.04 nM. Biodistribution studies in mice disclosed that [ 125I]IYM exhibited high and specific striatal uptake, with the striatal/ cerebellar uptake ratio being 14 at 120 min after injection. Furthermore, the striatal uptake of [ 125I]IYM was saturable, and [ 125I]IYM was displaced only by dopaminergic compounds. Ex vivo autoradiographic studies in rats further confirmed the high uptake and retention of this agent in the striatum and total blockade of its uptake by YM-09151-2. Thus, IYM showed specific binding to dopamine D 2 receptors in the rodent striatum and therefore holds great potential for use in in vivo dopamine D 2 receptor studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
